Genomic Characteristics and Response to Rucaparib and Enzalutamide in the Phase 1b RAMP Study of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients

Arpit Rao,¹ Charles J. Ryan,¹ David Morris,² Vasileios Assikis,³ Gautam Jha,¹ Adriel-John Ablaza,⁴ Jenn Habeck,⁴ Andrea Loehr,⁴ Jim Xiao,⁴ Esha A. Gangolli⁴

¹University of Minnesota, Minneapolis, USA; ²Urology Associates, P.C., Nashville, USA; ³Piedmont Cancer Institute, P.C., Atlanta, USA; ⁴Clovis Oncology, Inc., Boulder, USA

AACR Annual Meeting | April 10–15, 2021 | Virtual Meeting
Abstract 445
Introduction

- Rucaparib, a PARP inhibitor, is approved in the United States as monotherapy for patients with \textit{BRCA1/2}-mutated mCRPC who have been treated with AR-directed therapy and a taxane\textsuperscript{1}
- Enzalutamide is an AR-signaling inhibitor approved in the United States for the treatment of patients with CRPC or metastatic castration-sensitive prostate cancer\textsuperscript{2}
- Synthetic lethality has been observed, independent of DDR gene defects, when combining AR-directed therapy (eg, enzalutamide) and a PARP inhibitor for prostate cancer\textsuperscript{3,4}
- Preliminary results from the phase 1b RAMP study (NCT04179396) investigating the combination of rucaparib and enzalutamide in unselected patients with mCRPC have shown promising signs of antitumor activity, and its safety profile was consistent with that of each drug when used as monotherapy\textsuperscript{5}
  - Concomitant treatment with rucaparib and enzalutamide did not lead to significant changes in the PK profile for either agent or their metabolites (M324 and \textit{N}-desmethyl enzalutamide)
- Here, we evaluated the association between treatment response and genomic alterations of known clinical significance in mCRPC among patients from the RAMP study

AR, androgen receptor; CRPC, castration-resistant prostate cancer; DDR, DNA damage repair; mCRPC, metastatic castration-resistant prostate cancer; PARP, poly(ADP-ribose) polymerase; PK, pharmacokinetic.

Methods

- Enrolled patients had a histologically or cytologically confirmed adenocarcinoma or poorly differentiated carcinoma of the prostate after receiving 0–2 lines of AR-directed therapy (eg, enzalutamide, abiraterone) and ≤2 lines of chemotherapy for mCRPC; prior PARP inhibitor treatment was not allowed.
- Patients received rucaparib monotherapy (600 mg twice daily) during a 1-week run-in period, followed by rucaparib (600 mg twice daily) + enzalutamide (160 mg once daily) in continuous 28-day cycles.
- Dose-limiting toxicities were assessed during the first 2 cycles of combination treatment, and trough PK was evaluated for rucaparib and enzalutamide and their respective metabolites.

AR, androgen receptor; mCRPC, metastatic castration-resistant prostate cancer; PARP, poly(ADP-ribose) polymerase; PK, pharmacokinetic.
Methods (continued)

- Primary endpoints were PK and safety for the combination\(^1\)
- Secondary endpoints were the change from baseline in PSA levels and the objective response rate per modified RECIST and Prostate Cancer Clinical Trials Working Group 3
  - A confirmed PSA response was defined as a \(\geq 50\%\) reduction in PSA from baseline confirmed by a consecutive measurement \(\geq 3\) weeks later
- An exploratory objective was to evaluate the association between genomic alterations and clinical outcomes from treatment
  - Next-generation sequencing was performed on formalin-fixed paraffin-embedded tumor tissues or circulating cell-free DNA extracted from plasma samples to detect DDR gene alterations (eg, *BRCA1/2*) or genomic signatures associated with resistance to treatment
  - Sequencing was performed in Clinical Laboratory Improvement Amendments-approved facilities using the FoundationOne\(^\circledR\)CDx and FoundationOne\(^\circledR\)Liquid CDx laboratory-developed tests (Foundation Medicine, Inc., Cambridge, MA), which covered 324 and 70 cancer-related genes, respectively

DDR, DNA damage repair; PK, pharmacokinetic; PSA, prostate-specific antigen; RECIST, Response Evaluation Criteria In Solid Tumors version 1.1.
As of December 2, 2020, 8 patients had received treatment (Table 1).

- Seven (87.5%) out of 8 patients had at least 1 prior AR-directed therapy.

### Results

#### Table 1. Patient Demographics and Baseline Characteristics

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Patients (N=8)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, median (range), y</td>
<td>68.5 (56.0–79.0)</td>
</tr>
<tr>
<td>Race, n (%)</td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>7 (87.5)</td>
</tr>
<tr>
<td>Asian</td>
<td>1 (12.5)</td>
</tr>
<tr>
<td>ECOG PS, n (%)</td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>5 (62.5)</td>
</tr>
<tr>
<td>1</td>
<td>3 (37.5)</td>
</tr>
<tr>
<td>Baseline PSA, median (range), ng/mL</td>
<td>20.0 (2.5–155.0)</td>
</tr>
<tr>
<td>Gleason score ≥8, n (%)</td>
<td>7 (87.5)</td>
</tr>
<tr>
<td>Number of prior mCRPC therapies, n (%)</td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>1 (12.5)</td>
</tr>
<tr>
<td>1</td>
<td>1 (12.5)</td>
</tr>
<tr>
<td>2</td>
<td>4 (50.0)</td>
</tr>
<tr>
<td>≥3</td>
<td>2 (25.0)</td>
</tr>
<tr>
<td>Number of prior AR-directed therapies, n (%)</td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>1 (12.5)</td>
</tr>
<tr>
<td>1</td>
<td>6 (75.0)</td>
</tr>
<tr>
<td>2</td>
<td>1 (12.5)</td>
</tr>
</tbody>
</table>

Visit cutoff date: December 2, 2020.

- One patient had an unknown Gleason score.
- Defined based on class of agent and not disease status at time of treatment; does not include luteinizing hormone–releasing hormone analogues, first-generation antiandrogens, or hormones.

AR, androgen receptor; ECOG PS, Eastern Cooperative Oncology Group performance status; mCRPC, metastatic castration-resistant prostate cancer; PSA, prostate-specific antigen.
Results: Genomic Characteristics

- Genomic data were available for 6 (75%) of 8 treated patients, all of whom had received prior AR-directed therapy (Figure 1)
  - AR alterations, including rearrangements, amplifications, and single nucleotide variants, were observed in 4 (67%) patients (Table 2)
  - Mutations in TP53 were detected in 4 (67%) patients and PTEN in 2 (33%) patients
  - No BRCA1, BRCA2, or PALB2 alterations were detected
  - The only DDR gene alteration found was a subclonal (<1% allele frequency) alteration of CHEK2 in 1 (17%) patient (Figure 2)

AR, androgen receptor; DDR, DNA damage repair.
Figure 1. PSA Change From Baseline Over Time in Patients Treated With Rucaparib and Enzalutamide

Visit cutoff: December 2, 2020. PSA change from baseline were capped at 100% for visual clarity. The vertical dashed line indicates the start of the combination treatment following 1-week run-in with rucaparib monotherapy. AR, androgen receptor; DDR, DNA damage repair; PSA, prostate-specific antigen.
### Table 2. Genetic Alterations in AR

<table>
<thead>
<tr>
<th>Patient</th>
<th>Prior AR therapies</th>
<th>AR alteration (variant allelic frequency)</th>
<th>Best PSA change from baseline, %</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>Abiraterone, enzalutamide</td>
<td>Amplification, rearrangement</td>
<td>0.9</td>
</tr>
<tr>
<td>3</td>
<td>Abiraterone</td>
<td>Amplification, rearrangement</td>
<td>−16.9</td>
</tr>
<tr>
<td>4</td>
<td>Abiraterone</td>
<td>H875Y (3.1%), L702H (3.8%), rearrangement</td>
<td>−22.5</td>
</tr>
<tr>
<td>8</td>
<td>Abiraterone</td>
<td>T878A (0.8%)</td>
<td>−99.3</td>
</tr>
</tbody>
</table>

Visit cutoff date: December 2, 2020.
AR, androgen receptor; PSA, prostate-specific antigen.
Figure 2. Best Percent Change in PSA From Baseline in Patients Treated With Rucaparib and Enzalutamide

Visit cutoff: December 2, 2020. The horizontal dashed line indicates the threshold for PSA response, a 50% decrease from baseline.

AR, androgen receptor; CR, complete response; DDR, DNA damage repair; PSA, prostate-specific antigen; RECIST, Response Evaluation Criteria In Solid Tumors version 1.1.
Results: Efficacy

- Overall, 6 (75%) of 8 patients reported a decline in PSA from baseline, including 4 (50%) with a confirmed PSA response (Figure 2)
- Patients previously treated with AR-directed therapies demonstrated reductions in PSA following the combination treatment even in the presence of multiple AR alterations and in the absence of DDR gene alterations (Table 2)
  - Patient 4 had 3 AR alterations including AR H875Y (VAF, 3.1%), AR L702H (3.8%), and rearrangement and reported a best PSA change from baseline of −22.5%
  - Patient 8, with a low allele frequency point mutation in AR T878A (VAF, <1%), had the greatest reduction in PSA from baseline (best PSA change of −99.3%) and achieved a confirmed complete radiographic response
    - The patient also had a TP53 alteration (TP53 R248Q) and TMPRSS2:ERG gene fusion
- At the time of data cutoff, 3 patients were still ongoing on study treatment, including 2 (25%) who remained on study for >6 cycles

AR, androgen receptor; DDR, DNA damage repair; PSA, prostate-specific antigen; VAF, variant allele frequency.
Summary

- Unselected patients with mCRPC who had progressed on AR-directed therapies reported declines in PSA following treatment with the combination of rucaparib 600 mg twice daily and enzalutamide 160 mg once daily
  - These declines in PSA were observed even in the presence of AR alterations and the absence of DDR gene alterations
- Combination treatment with rucaparib and enzalutamide in patients with mCRPC had a safety profile consistent with that associated with each drug as monotherapy and had no clinically significant drug-drug interactions
- These data support further study of the rucaparib and enzalutamide combination
  - The phase 3 CASPAR study (NCT04455750) is enrolling biomarker-unselected patients with mCRPC

AR, androgen receptor; DDR, DNA damage repair; mCRPC, metastatic castration-resistant prostate cancer; PSA, prostate-specific antigen.

Genomic Characteristics and Response to Rucaparib and Enzalutamide in the Phase 1b RAMP Study of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients

Also available at:

Copies of this e-poster obtained through Quick Response (QR) codes and/or web links are for personal use only and may not be reproduced without written permission of the authors.

This study was funded by Clovis Oncology, Inc. Medical writing and editorial support funded by Clovis Oncology, Inc., were provided by Shelly Lim and Frederique H. Evans of Ashfield MedComms, an Ashfield Health company.